Literature DB >> 20802331

Multiresistant Gram-negative infections: a global perspective.

Jennifer Ho1, Paul A Tambyah, David L Paterson.   

Abstract

PURPOSE OF REVIEW: Multiresistant Gram-negative infections are an increasing problem in hospitals and healthcare facilities worldwide. While much attention has been paid to Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus lately, the importance of Gram-negative nosocomial infections has also been recognized globally. RECENT
FINDINGS: Recent reports have described the spread of carbapenemase-producing Klebsiella pneumoniae across North America. In addition, many strains of Pseudomonas and Acinetobacter in Asia are resistant to all known antibiotics. The global epidemiology of multiresistant Gram-negative pathogens seems to vary by continent. There are very few existing agents which can be used for these pathogens and there are limited options on the horizon. This limited therapeutic armamentarium has been an impetus for novel approaches including combination therapies and increased attention to infection control and prevention efforts.
SUMMARY: Clinicians need to be aware of the rising problem of resistance in nosocomial and community-acquired Gram-negative pathogens. Novel agents are urgently needed to combat these infections and innovative infection control strategies need to be devised to protect our vulnerable patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20802331     DOI: 10.1097/QCO.0b013e32833f0d3e

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  62 in total

1.  In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens.

Authors:  Michael Hornsey; Christopher Longshaw; Lynette Phee; David W Wareham
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

2.  Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.

Authors:  Rajbharan Yadav; Cornelia B Landersdorfer; Roger L Nation; John D Boyce; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

Review 3.  Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem.

Authors:  Carl Llor; Lars Bjerrum
Journal:  Ther Adv Drug Saf       Date:  2014-12

4.  Structural and Functional Studies of Bacterial Enolase, a Potential Target against Gram-Negative Pathogens.

Authors:  Jolanta Krucinska; Eric Falcone; Heidi Erlandsen; Akram Hazeen; Michael N Lombardo; Alexavier Estrada; Victoria L Robinson; Amy C Anderson; Dennis L Wright
Journal:  Biochemistry       Date:  2019-02-15       Impact factor: 3.162

5.  Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies.

Authors:  Henri Merdjan; Manickam Rangaraju; Antoine Tarral
Journal:  Clin Drug Investig       Date:  2015-05       Impact factor: 2.859

6.  The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Zakuan Z Deris; Heidi H Yu; Kathryn Davis; Rachel L Soon; Jovan Jacob; Caron K Ku; Anima Poudyal; Phillip J Bergen; Brian T Tsuji; Jurgen B Bulitta; Alan Forrest; David L Paterson; Tony Velkov; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

7.  Mechanism of Escherichia coli resistance to Pyrrhocoricin.

Authors:  Shalini Narayanan; Joyanta K Modak; Catherine S Ryan; Jose Garcia-Bustos; John K Davies; Anna Roujeinikova
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

8.  Use of imipenem to detect KPC, NDM, OXA, IMP, and VIM carbapenemase activity from gram-negative rods in 75 minutes using liquid chromatography-tandem mass spectrometry.

Authors:  M V Kulkarni; A N Zurita; J S Pyka; T S Murray; M E Hodsdon; D R Peaper
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

9.  Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial.

Authors:  Anthony D Harris; Lisa Pineles; Beverly Belton; J Kristie Johnson; Michelle Shardell; Mark Loeb; Robin Newhouse; Louise Dembry; Barbara Braun; Eli N Perencevich; Kendall K Hall; Daniel J Morgan; Syed K Shahryar; Connie S Price; Joseph J Gadbaw; Marci Drees; Daniel H Kett; L Silvia Muñoz-Price; Jesse T Jacob; Loreen A Herwaldt; Carol A Sulis; Deborah S Yokoe; Lisa Maragakis; Matthew E Lissauer; Marcus J Zervos; David K Warren; Robin L Carver; Deverick J Anderson; David P Calfee; Jason E Bowling; Nasia Safdar
Journal:  JAMA       Date:  2013-10-16       Impact factor: 56.272

10.  Impact of Gram-negative bacteria on the treatment of venous leg ulcers.

Authors:  Wibke L Engelberg; Martin Dörler; Markus Stücker; Stefanie Reich-Schupke
Journal:  Int Wound J       Date:  2018-08-05       Impact factor: 3.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.